Drug Profile
NI 204
Alternative Names: NI-204; TDI 200Latest Information Update: 20 Oct 2022
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Developer ALS Therapy Development Institute; Eledon Pharmaceuticals; Neurimmune Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors; Superoxide dismutase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 20 Oct 2022 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (IV)
- 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
- 14 Sep 2020 Anelixis Therapeutics has been acquired and merged into Novus Therapeutics